2. Search Result
Search Result
Results for "

Cd

" in MedChemExpress (MCE) Product Catalog:

931

Inhibitors & Agonists

1

Screening Libraries

5

Fluorescent Dye

16

Biochemical Assay Reagents

81

Peptides

8

MCE Kits

456

Inhibitory Antibodies

148

Natural
Products

2310

Recombinant Proteins

223

Isotope-Labeled Compounds

288

Antibodies

4

Click Chemistry

118

Oligonucleotides

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-100891
    CD80-IN-3

    		CD28 Inflammation/Immunology
    CD80-IN-3, a potent CD80 inhibitor, inhibits CD80/CD28 interaction with an EC50 of 630 nM and a Kd of 125 nM.
    CD80-IN-3
  • HY-131967
    CD73-IN-4

    		CD73 Inflammation/Immunology Cancer
    CD73-IN-4 is a potent and selective methylenephosphonic acid CD73 inhibitor, with an IC50 of 2.6 nM for human CD73. CD73-IN-4 is potential for the research of cancer immunology .
    CD73-IN-4
  • HY-19047
    CD-349

    		Others Others
    CD-349 is an active compound.
    CD-349
  • HY-128977
    CD235

    		Epigenetic Reader Domain Cancer
    CD235 is a structurally similar analogue of CD161. CD161 is a potent and orally bioavailable BET bromodomain inhibitor .
    CD235
  • HY-111366
    CD12681

    		ROR Inflammation/Immunology
    CD12681 (compound 14) is a potent and selective RORγ inverse agonist with IC50 of 19 nM and 10 nM for RORγ GAL4 and CD4-IL-17 cells, respectively. CD12681 decreases the IL-17 inflammatory cell recruitment. CD12681 has the potential for the research of psoriasis .
    CD12681
  • HY-162554
    CD73-IN-15

    		CD73 Inflammation/Immunology Cancer
    CD73-IN-15 (compound 12f) is a potent inhibitor of CD73, with the IC50 of 60 nM. CD73-IN-15 plays an important role in cancer research .
    CD73-IN-15
  • HY-144209
    CD73-IN-6

    		CD73 Cancer
    CD73-IN-6 is a CD73 inhibitor extracted from patent WO2022007677A1 compound 2. CD73-IN-6 can be used for the research of cancer .
    CD73-IN-6
  • HY-162918
    CD73-IN-17

    		CD73 Cancer
    CD73-IN-17 (compound 19) is a CD73 inhibitor with IC50 of 0.1 μM for hCD73. CD73-IN-17 can be used in anti-cancer research .
    CD73-IN-17
  • HY-147594
    CD73-IN-13

    		CD73 Cancer
    CD73-IN-13 is a potent inhibitor of CD73. CD73 is closely associated with tumor growth, angiogenesis and metastasis. CD73-IN-13 be used for preparing a medicament for tumor-related diseases (extracted from patent CN114437039A, compound 7) .
    CD73-IN-13
  • HY-169189
    CD73-IN-18

    		CD73 Cancer
    CD73-IN-18 (compound 35j) is an orally available inhibitor of extracellular 5-nucleotidase (CD73). CD73-IN-18 can be used in anti-cancer research .
    CD73-IN-18
  • HY-160624
    CD 10899

    		Polo-like Kinase (PLK) Cancer
    CD 10899 is a hydroxylated metabolite of Volasertib (HY-12137). CD 10899 is pharmacologically active against Polo-like kinase 1 (PLK1) (IC50: 6 nM). Volasertib is an orally active, highly potent and ATP-competitive PLK1 inhibitor. CD 10899 can be used for research of cancer .
    CD 10899
  • HY-147593
    CD73-IN-12

    		CD73 Cancer
    CD73-IN-12 is a potent inhibitor of CD73. CD73 is closely associated with tumor growth, angiogenesis and metastasis. CD73-IN-12 be used for preparing a medicament for tumor-related diseases (extracted from patent CN114437038A, compound 9) . CD73-IN-12 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    CD73-IN-12
  • HY-112273
    CD532

    		Aurora Kinase Cancer
    CD532 is a potent Aurora A kinase inhibitor with an IC50 of 45 nM. CD532 has the dual effect of blocking Aurora A kinase activity and driving degradation of MYCN. CD532 also can directly interact with AURKA and induces a global conformational shift. CD532 can be used for the research of cancer .
    CD532
  • HY-112273A
    CD532 hydrochloride

    		Aurora Kinase Cancer
    CD532 hydrochloride is a potent Aurora A kinase inhibitor with an IC50 of 45 nM. CD532 hydrochloride has the dual effect of blocking Aurora A kinase activity and driving degradation of MYCN. CD532 hydrochloride also can directly interact with AURKA and induces a global conformational shift. CD532 hydrochloride can be used for the research of cancer .
    CD532 hydrochloride
  • HY-145334
    CD73-IN-5

    		CD73 Cancer
    CD73-IN-5 is a potent and selective non-nucleotide small molecule inhibitor of CD73 (IC50 = 19 nM).
    CD73-IN-5
  • HY-W177546
    CD00509

    		Phosphodiesterase (PDE) Cancer
    CD00509 is a Tdp1 inhibitor, with an IC50 value of 0.71 μM. CD00509 can sensitize breast cancer cells to Camptothecin (HY-16560). CD00509 has anti-tumor activity .
    CD00509
  • HY-137246
    CD73-IN-3

    		CD73 Cancer
    CD73-IN-3 is a potent CD73 inhibitor (IC50=7.3 nM in Calu6 human cell assay). CD73-IN-3, example 2 extracted from patent WO2019168744 A1, has the potential for cancer research .
    CD73-IN-3
  • HY-147588
    CD73-IN-7

    		CD73 Cancer
    CD73-IN-7 is a potent inhibitor of CD73. CD73 can catalyze the production of adenosine from extracellular 5'-phosphate adenosine (5'-AMP), and adenosine can induce immunosuppressive effects and promote tumor proliferation and/or metastasis. CD73-IN-7 be used for preparing a medicament for tumor-related diseases (extracted from patent WO2022052886A1, compound 13) .
    CD73-IN-7
  • HY-147589
    CD73-IN-8

    		CD73 Cancer
    CD73-IN-8 is a potent inhibitor of CD73. CD73 can catalyze the production of adenosine from extracellular 5'-phosphate adenosine (5'-AMP), and adenosine can induce immunosuppressive effects and promote tumor proliferation and/or metastasis. CD73-IN-8 be used for preparing a medicament for tumor-related diseases (extracted from patent WO2022052886A1, compound 57) .
    CD73-IN-8
  • HY-147590
    CD73-IN-9

    		CD73 Inflammation/Immunology
    CD73-IN-9 is a potent inhibitor of CD73. CD73 can catalyze the production of adenosine from extracellular 5'-phosphate adenosine (5'-AMP), and adenosine can induce immunosuppressive effects and promote tumor proliferation and/or metastasis. CD73-IN-9 be used for preparing a medicament for tumor-related diseases (extracted from patent WO2022068929A1, compound 2) .
    CD73-IN-9
  • HY-147592
    CD73-IN-11

    		CD73 Inflammation/Immunology Cancer
    CD73-IN-11 is a potent inhibitor of CD73. CD73 can catalyze the production of adenosine from extracellular 5'-phosphate adenosine (5'-AMP), and adenosine can induce immunosuppressive effects and promote tumor proliferation and/or metastasis. CD73-IN-11 be used for preparing a medicament for tumor-related diseases (extracted from patent WO2022068929A1, compound 24) .
    CD73-IN-11
  • HY-147591
    CD73-IN-10

    		CD73 Inflammation/Immunology Cancer
    CD73-IN-10 is a potent inhibitor of CD73. CD73 can catalyze the production of adenosine from extracellular 5'-phosphate adenosine (5'-AMP), and adenosine can induce immunosuppressive effects and promote tumor proliferation and/or metastasis. CD73-IN-10 be used for preparing a medicament for tumor-related diseases (extracted from patent WO2022068929A1, compound 4) .
    CD73-IN-10
  • HY-131435
    CD73-IN-2

    		CD73 Cancer
    CD73-IN-2 is a potent CD73 inhibitor extracted from WO2020151707A1, example 1, has an IC50 of 0.09 nM .
    CD73-IN-2
  • HY-152074
    CD73-IN-14

    		CD73 Cancer
    D73-IN-14 is a potent, selective and orally active CD73 inhibitor with an IC50 value of 0.17 nM. CD73-IN-14 increases the number of tumor-infiltrating CD8 + cells and shows anti-tumor activity . CD73-IN-14 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    CD73-IN-14
  • HY-153085
    CD19 CAR circRNA

    		CD19 Inflammation/Immunology Cancer
    CD19 CAR circRNA will express CD19 car protein, and can be used in chimeric antigen receptor T cell immunotherapy (CAR-CD19). The CD19 car is a chimeric antigen receptor. Among them, CD19 is a CD molecule expressed by B cells (i.e. leukocyte differentiation antigen), an important membrane antigen involved in B cell proliferation, differentiation, activation and antibody production, and can also promote BCR signal transduction.
    CD19 CAR circRNA
  • HY-103695
    CD73-IN-1

    		CD73 Cancer
    CD73-IN-1 is an inhibitor of CD73 which can be used in the treatment of cancer extracted from patent WO 2017153952 A1, example 80.
    CD73-IN-1
  • HY-153084
    CD19 CAR mRNA (Mouse)
    1 Publications Verification

    		 CD19 Inflammation/Immunology Cancer
    CD19 CAR mRNA (Mouse) will express mouse CD19 CAR protein, and can be used in chimeric antigen receptor T cell immunotherapy (CAR-CD19). The CD19 CAR is a chimeric antigen receptor. Among them, CD19 is a CD molecule expressed by B cells (i.e. leukocyte differentiation antigen), an important membrane antigen involved in B cell proliferation, differentiation, activation and antibody production, and can also promote BCR signal transduction.
    CD19 CAR mRNA (Mouse)
  • HY-153084A
    CD19 CAR mRNA (Human)

    		CD19 Cancer
    CD19 CAR mRNA (Human) will express Human CD19 CAR protein, and can be used in chimeric antigen receptor T cell immunotherapy (CAR-CD19). The CD19 CAR is a chimeric antigen receptor. Among them, CD19 is a CD molecule expressed by B cells (i.e. leukocyte differentiation antigen), an important membrane antigen involved in B cell proliferation, differentiation, activation and antibody production, and can also promote BCR signal transduction.
    CD19 CAR mRNA (Human)
  • HY-153234
    CD19 car circRNA-LNP

    		CD19 Liposome Inflammation/Immunology Cancer
    CD19 car circRNA-LNP is a lipid nanoparticle (LNP) containing CD19 car circRNA, suitable for detection of RNA delivery, translation efficiency, cell viability, etc. CD19 car circRNA can be used in chimeric antigen receptor T cell immunotherapy (CAR-CD19). The CD19 car is a chimeric antigen receptor. Among them, CD19 is a CD molecule expressed by B cells (i.e. leukocyte differentiation antigen), an important membrane antigen involved in B cell proliferation, differentiation, activation and antibody production, and can also promote BCR signal transduction .
    CD19 car circRNA-LNP
  • HY-P10091
    CD24/Siglec-10 blocking peptide, CSBP

    		PD-1/PD-L1 Cancer
    CD24/Siglec-10 blocking peptide, CSBP can not only block the interaction of CD24/Siglec-10 but also PD-1/PD-L1. CD24/Siglec-10 blocking peptide, CSBP can induce the phagocytosis of tumor cell .
    CD24/Siglec-10 blocking peptide, CSBP
  • HY-162917
    CD73-IN-16

    		CD73 Cancer
    CD73-IN-16 (compound 18) is an inhibitor of hCD73 with IC50 values of 0.28 μM .
    CD73-IN-16
  • HY-146081
    CD22 ligand-1

    		CD22 Cancer
    CD22 ligand-1 (compound 12) is a potent and selective CD22 ligand with KD of 0.335, 30.7 µM for hCD22 and MAG, respectively. CD22 ligand-1 has the potential for the research of B-cell related disease .
    CD22 ligand-1
  • HY-144399
    CD33 splicing modulator 1

    		Others Neurological Disease
    CD33 splicing modulator 1 (Compound 1) is a CD33 splicing modulator. CD33/Siglec 3 is a myeloid lineage cell surface receptor that is known to regulate microglia activity. CD33 splicing modulator 1 increases exon 2 skipping in cellular mRNA pools. CD33 splicing modulator 1 has the potential for the research of neurodegenerative disease including Alzheimer's disease .
    CD33 splicing modulator 1
  • HY-144399A
    CD33 splicing modulator 1 hydrochloride

    		Others Neurological Disease
    CD33 splicing modulator 1 (Compound 1) hydrochloride is a CD33 splicing modulator. CD33/Siglec 3 is a myeloid lineage cell surface receptor that is known to regulate microglia activity. CD33 splicing modulator 1 hydrochloride increases exon 2 skipping in cellular mRNA pools. CD33 splicing modulator 1 hydrochloride has the potential for the research of neurodegenerative disease including Alzheimer's disease .
    CD33 splicing modulator 1 hydrochloride
  • HY-123999
    CD38 inhibitor 1
    5+ Cited Publications

    		 CD38 Metabolic Disease
    CD38 inhibitor 1 (compound 78c) is a potent CD38 inhibitor with IC50s of 7.3 nM and 1.9 nM for hCD38 and mouse CD38 .
    CD38 inhibitor 1
  • HY-153233
    CD19 car mRNA (Mouse)-LNP

    		CD19 Liposome Inflammation/Immunology Cancer
    CD19 car mRNA (Mouse)-LNP is a lipid nanoparticle (LNP) containing CD19 car mRNA, suitable for detection of RNA delivery, translation efficiency, cell viability, etc. CD19 car mRNA can be used in chimeric antigen receptor T cell immunotherapy (CAR-CD19). The CD19 car is a chimeric antigen receptor. Among them, CD19 is a CD molecule expressed by B cells (i.e. leukocyte differentiation antigen), an important membrane antigen involved in B cell proliferation, differentiation, activation and antibody production, and can also promote BCR signal transduction .
    CD19 car mRNA (Mouse)-LNP
  • HY-P3444
    CD31

    PECAM-1

    		 SHP2 Bacterial Metabolic Disease Inflammation/Immunology
    CD31 (PECAM-1) is platelet endothelial cell adhesion molecule-1, serves as the endothelial cell-specific receptor of clostridium perfringens b-Toxin (CPB). CD31 is also an ER-MP12 antigen, acts as a linker between mechanical stress, metabolism and inflammation. CD31 peptide is able to sustain phosphorylation of the CD31 ITIM686 and of SHP2 and to inhibit TCR-induced T-cell activation - .
    CD31
  • HY-144988
    CD38 inhibitor 2

    		CD38 Cancer
    CD38 inhibitor 2 is a potent CD38 inhibitor (IC50 = 0.01 ~ 0.1 μΜ).
    CD38 inhibitor 2
  • HY-107399
    CD3254
    3 Publications Verification

    		 RAR/RXR Metabolic Disease Cancer
    CD3254 a potent and selective retinoid-X-receptor (RXR) agonist .
    CD3254
  • HY-108527
    CD1530

    		RAR/RXR Cancer
    CD1530 is a selective RARγ agonist with an Kd of 150 nM . CD1530 has been used in combination with bexarotene to inhibit oral carcinogenesis induced by the carcinogen 4-nitroquinoline 1-oxide in a mouse model of human oral-cavity and esophageal squamous-cell carcinoma .
    CD1530
  • HY-156120
    CD38 inhibitor 3

    		CD38 Metabolic Disease
    CD38 inhibitor 3 (compound 1) is a potent CD38 inhibitor (IC50=11 nM). CD38 inhibitor 3 can promote mitochondrial biogenesis, reduce lactate levels, and increase NAD+ content and Nrf2 expression. In a model of mitochondrial myopathy, CD38 inhibitor 3 increases muscle contraction/development and improves exercise tolerance in Pus1 -/- mice .
    CD38 inhibitor 3
  • HY-100532
    CD437
    3 Publications Verification

    AHPN

    		 RAR/RXR Autophagy Cancer
    CD437 is a selective Retinoic Acid Receptor γ (RARγ) agonist.
    CD437
  • HY-P990017
    Englumafusp alfa

    Cd19-4-1BBL; RO7227166; RG6076

    		 CD19 Cancer
    Englumafusp alfa (CD19-4-1BBL; RO7227166) is a fusion construct comprised of a CD19-specific antibody domain fused to a trimerized extracellular domains of human 41BBL. Englumafusp alfa promotes CD19-specific 4-1BB cross-linking on the surface of T and NK cells .
    Englumafusp alfa
  • HY-108533
    CD2314

    		RAR/RXR Cancer
    CD2314 is a potent and selective RARβ receptor agonist with a Kd of 195 nM in S91 melanoma cells .
    CD2314
  • HY-P3444A
    CD31 TFA

    PECAM-1 TFA

    		 SHP2 Bacterial Metabolic Disease Inflammation/Immunology
    CD31 (PECAM-1) TFA is platelet endothelial cell adhesion molecule-1, serves as the endothelial cell-specific receptor of clostridium perfringens b-Toxin (CPB). CD31 TFA is also an ER-MP12 antigen, acts as a linker between mechanical stress, metabolism and inflammation. CD31 TFA peptide is able to sustain phosphorylation of the CD31 ITIM686 and of SHP2 and to inhibit TCR-induced T-cell activation - .
    CD31 TFA
  • HY-100256
    Trifarotene

    Cd5789

    		 RAR/RXR Autophagy Inflammation/Immunology
    Trifarotene (CD5789) is a potent and selective RARγ agonist. Trifarotene (CD5789) shows ∼65-fold and ∼16-fold selectivitiy for the RARγ (EC50=7.7 nM) over RARα (EC50=500 nM) and RARβ (EC50=125 nM), respectively .
    Trifarotene
  • HY-100532S
    CD437-13C6

    AHPN-13C6

    		 Isotope-Labeled Compounds RAR/RXR Autophagy Cancer
    CD437- 13C6 is the 13C- and deuterium labeled CD437. CD437 is a selective Retinoic Acid Receptor γ (RARγ) agonist.
    CD437-13C6
  • HY-107437
    CD2665

    		RAR/RXR Metabolic Disease
    CD2665 is an orally active and selective RAR-β,γ antagonist, with Kd values of 306 nM, 110 nM for RAR-β and RAR-γ, repectively .
    CD2665
  • HY-RS02188
    CD109 Human Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    CD109 Human Pre-designed siRNA Set A contains three designed siRNAs for CD109 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    CD109 Human Pre-designed siRNA Set A
    CD109 Human Pre-designed siRNA Set A
  • HY-RS02189
    CD14 Human Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    CD14 Human Pre-designed siRNA Set A contains three designed siRNAs for CD14 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    CD14 Human Pre-designed siRNA Set A
    CD14 Human Pre-designed siRNA Set A

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: